VC-backed ReViral appoints CEO
ReViral Ltd, a developer of novel, antiviral compounds that target respiratory syncytial virus, has named Alex C. Sapir as CEO. Sapir is the former president and CEO of Dova Pharmaceuticals. ReViral is backed by New Leaf Venture Partners, Novo Ventures, Perceptive Advisors, Andera Partners, OrbiMed and Brace Pharma Capital.
11 June 2019•4 mins read
